American Virtual Cloud (AVCT)

AVCT NEWS

Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting By AVACTA - 4 days ago

Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data … [+5414 chars]...

Read more
Top Stock
CurrencyPrice Chg
BA
185.46 2.57
1.41%
CVX
138.5 2.24
1.64%
CAT
323.68 9.72
3.1%
INTC
20.62 0.64
3.2%
MSFT
435.28 9.88
2.32%
DIS
92.49 1.68
1.85%
DOW
30.42 -0.11
-0.36%
CSCO
59.33 1.21
2.08%
GS
566.1 12.27
2.22%